Monte Rosa's broad molecular glue degrader plan comes unstuck, but prostate cancer work continues
Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. Biomarker-positive patients were rarer than expected in some tumor types, prompting the biotech to focus MRT-2359 development on prostate cancer while continuing to advance its alliance with Novartis toward phase 2.
Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. Biomarker-positive patients were rarer than expected in some tumor types, prompting the biotech to focus MRT-2359 development on prostate cancer while continuing to advance its alliance with Novartis toward phase 2.
